The deadly combination of a keto diet and SGLT-2 inhibitors: A case of euglycemic ketoacidosis
Abstract
Diabetic ketoacidosis is an acute and serious complication of diabetes mellitus, which usually occurs in type 1 but is not uncommon in type 2 diabetes patients. It is characterized by hyperglycemia, metabolic acidosis, and ketone bodies in the blood or urine. A subgroup of patients may present without signs of hyperglycemia with normal blood glucose levels, thus posing a diagnostic challenge. Here, we report a case of a 42-year-old gentleman who presented to the emergency room and was diagnosed with euglycemic diabetic ketoacidosis 3 days after starting Empagliflozin along with a strict low-carbohydrate diet. Extensive workup failed to demonstrate any other factor, such as infection, that may have led to this complication. This article aims to raise awareness among clinicians to be aware of this diagnosis in the differentials in patients taking SGLT-2 inhibitors who are also on a strict low-carbohydrate diet.
J Assoc Clin Endocrinol Diabetol Bangladesh, January 2024;4(1): 39-42
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.